TY - JOUR
T1 - Challenges associated with metal chelation therapy in alzheimer's disease
AU - Hegde, Muralidhar L.
AU - Bharathi, P.
AU - Suram, Anitha
AU - Venugopal, Chitra
AU - Jagannathan, Ramya
AU - Poddar, Pankaj
AU - Srinivas, Pullabhatla
AU - Sambamurti, Kumar
AU - Rao, Kosagisharaf Jagannatha
AU - Scancar, Janez
AU - Messori, Luigi
AU - Zecca, Luigi
AU - Zatta, Paolo
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2009
Y1 - 2009
N2 - A close association between brain metal dishomeostasis and the onset and/or progression of Alzheimer's disease (AD) has been clearly established in a number of studies, although the underlying biochemical mechanisms remain obscure. This observation renders chelation therapy an attractive pharmacological option for the treatment of this disease. However, a number of requirements must be fulfilled in order to adapt chelation therapy to AD so that the term "metal targeted strategies" seems now more appropriate. Indeed, brain metal redistribution rather than brain metal scavenging and removal is the major goal of this type of intervention. The most recent developments in metal targeted strategies for AD will be discussed using, as useful examples, clioquinol, curcumin, and epigallocatechin, and the future perspectives will also be outlined.
AB - A close association between brain metal dishomeostasis and the onset and/or progression of Alzheimer's disease (AD) has been clearly established in a number of studies, although the underlying biochemical mechanisms remain obscure. This observation renders chelation therapy an attractive pharmacological option for the treatment of this disease. However, a number of requirements must be fulfilled in order to adapt chelation therapy to AD so that the term "metal targeted strategies" seems now more appropriate. Indeed, brain metal redistribution rather than brain metal scavenging and removal is the major goal of this type of intervention. The most recent developments in metal targeted strategies for AD will be discussed using, as useful examples, clioquinol, curcumin, and epigallocatechin, and the future perspectives will also be outlined.
KW - Alzheimer's disease
KW - Clioquinol
KW - Cuprizone
KW - Metal dishomeostasis
KW - Metal ions
KW - Nanomedicine
KW - Parkinson's disease
KW - Polyphenols
UR - http://www.scopus.com/inward/record.url?scp=67849090892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67849090892&partnerID=8YFLogxK
U2 - 10.3233/JAD-2009-1068
DO - 10.3233/JAD-2009-1068
M3 - Review article
C2 - 19363258
AN - SCOPUS:67849090892
SN - 1387-2877
VL - 17
SP - 457
EP - 468
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
IS - 3
ER -